Bristol Myers Squibb Receives European Commission Approval for Inrebic® for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis Biotech Investing
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Medical Device Investing
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi , a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma Biotech Investing
Bristol Myers Squibb to Participate in Guggenheim's Virtual Healthcare Talks | 2021 Oncology Day Biotech Investing
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate Medical Device Investing
